Frank Lezoualc’h has more than 25 years of experience in medical research. He received his PhD in molecular endocrinology from the University Pierre & Marie Curie, Paris and was a postdoctoral fellow at the Max-Planck Institute in Munich.
He was appointed Research Director at Inserm, University Paris-Sud in 2005 and became the head of the laboratory “Signaling and Pathophysiology of Heart failure and Aging” at Inserm, Toulouse University in 2010.
He is studying intracellular signalosomes activated by acute or chronic cardiac stress (ischemia, adrenergic overdrive, metabolic alteration) that promote pathological cardiac remodeling. His research aims to identify relevant targets for the treatment of heart failure and arrhythmia.
Frank Lezoualc’h was pioneer in the identification of Epac disease implication and Epac1 pharmacological inhibitors. He has published more than 110 research papers (H-index=47, 15038 citations), several of which appeared in prominent journals such as Nature Cell Biology, PNAS, Circulation, Circulation Research, etc. He is author of 10 patents relative to the discovery of novel therapeutic targets and compounds. He is regularly invited to speak internationally on his research on Epac.
